OTCs stronger for Taisho in first quarter
This article was originally published in Scrip
Taisho saw its mainstay over-the-counter products rebound in the first quarter to June 30th, when net sales from self-medication operations rose by 11% to ¥38.6 billion ($358.9 million). Prescription sales were 4% higher at ¥23.2 billion, but were held back by a 7% year-on-year fall for top product Clarith (clarithromycin) to ¥5.7 billion following the general reimbursement price cut in April. Group net profit for the quarter was 28% higher at ¥7.7 billion, boosting earnings per share by the same margin to ¥25.87. Helped by cost cutting, the operating figure jumped by 42% to ¥11.6 billion.